MiR-34a may Function as Potential Biomarker for Remission after Traumatic Spinal Cord Injury
Related Experiment Video
Updated: Dec 24, 2025
Experimental Strategies to Bridge Large Tissue Gaps in the Injured Spinal Cord after Acute and Chronic Lesion
Published on: April 5, 2016
Background:
Emerging evidence has manifested that many microRNAs (miRNAs) exert crucial roles in the responses and remission process of traumatic spinal cord injury (TSCI). The present study aimed to investigate clinical significance of miR-34a concerning the assessment of neurological remission and prognosis after TSCI.
Methods:
We examined the serum levels of miR-34a in patients with TSCI and healthy controls through real-time polymerase chain reaction (RT-qPCR) assay. Then, receiver operating characteristic (ROC) curve was used to determine the diagnostic value of miR-34a in TSCI. Finally, we detected the expression levels of miR-34a from serum samples over a 12-week period.
Results:
The results of our study demonstrated that miR-34a was significantly down-regulated in TSCI patients compared with healthy controls. miR-34a may function a potential biomarker for TSCI diagnosis with an area under curve (AUC) of 0.8020. The expression of miR-34a was increased in the remission group compared to the non-remission group after 12 weeks post-injury. The expression of miR-34a was negatively related to TNF-alpha, IL-6, and IL-8.
Conclusions:
Measuring serum expression level of miR-34a over time may be used in tracking the process and neurological remission of TSCI.
Insights
Serum miR-34a levels are significantly lower in patients with traumatic spinal cord injury (TSCI). Monitoring miR-34a may help assess neurological recovery and prognosis after TSCI.
Area of Science:
- Biochemistry
- Molecular Biology
- Neuroscience
Background:
- MicroRNAs (miRNAs) play key roles in the response and recovery from traumatic spinal cord injury (TSCI).
- Investigating specific miRNAs like miR-34a is crucial for understanding TSCI pathophysiology and outcomes.
Purpose of the Study:
- To determine the clinical significance of miR-34a in assessing neurological remission and prognosis following TSCI.
- To evaluate miR-34a as a potential diagnostic biomarker for TSCI.
Main Methods:
- Serum miR-34a levels were quantified in TSCI patients and healthy controls using real-time quantitative polymerase chain reaction (RT-qPCR).
- Receiver operating characteristic (ROC) curve analysis was employed to assess the diagnostic accuracy of miR-34a.
- Serum miR-34a expression was monitored over a 12-week period post-injury.
Main Results:
- miR-34a was significantly downregulated in TSCI patients compared to healthy individuals.
- miR-34a demonstrated potential as a diagnostic biomarker for TSCI with an Area Under the Curve (AUC) of 0.8020.
- miR-34a expression increased in patients who showed neurological remission versus those who did not, and it was negatively correlated with inflammatory markers (TNF-alpha, IL-6, IL-8).
Conclusions:
- Serum miR-34a levels can serve as a valuable indicator for tracking the progression and neurological remission in TSCI patients.
- Dynamic monitoring of miR-34a expression may offer insights into recovery trajectories and therapeutic responses in TSCI.
